Paradise Entertainment Limited · HKEX:1180
Paradise Entertainment — LifeTec Group — Investor Presentation (July 2004)
29 slides from Paradise Entertainment's investor presentation, July 2004
Slide 1: LifeTec Group Limited Investor Presentation
LifeTec Group Limited Investor Presentation July 2004 1 www.hk1180.com
Slide 2: R&D And Marketing Excellence
R&D And Marketing Excellence LifeTec R&D Marketing § World class scientists: § Category I drug Wei Jia Professor Hsiang Fu Kung Professor Michael Yang § Cover about 800 hospitals in Dr. Jun Cheng China Professor Si Chong Wen § South East Asia markets 2/10 www.hk1180.com
Slide 3: Target World's Largest HBV Drug Market
Target World’s Largest HBV Drug Market No. of HBV Carriers China 120 m South East Asia 45 m India 80 m H.K. Europe 4m U.S. 3m Other Countries 148 m Low Infection Region World Total 400 m Medium Infection Region High Infection Region Source: The PRC Health Yearbook, Deutsche Bank Research, World Heal
Slide 4: Wei Jia – New Generation Category I Drug For Hepatitis
Wei Jia – New Generation Category I Drug For Hepatitis § One of only 19 Category I drugs approved since 1949 4/10 www.hk1180.com
Slide 5: Road Map For Liver Drugs
Road Map For Liver Drugs Liver Damaged by: virus, trauma, alcohol and toxin Cirrhosis Liver Liver Failure Hepatitis Fibrosis (Acute) (Chronic) Liver Cancer rhALR Wei Jia Fibroscutum 5/10 www.hk1180.com
Slide 6: Genetic Drugs Under Development
Genetic Drugs Under Development Fibroscutum and rhALR § Each has worldwide market over US$3 billion § Developed by world’s top researchers in respective areas 6/10 www.hk1180.com
Slide 7: New Drugs Under Clinical Trials
New Drugs Under Clinical Trials § Pazufloxazin - For bronchitis, complicated urinary tract infections, gonorrhea § Compound Dextromethorphan Hydrobromide Buccal Tablets - For common cold, respiratory tract infections, bronchitis § Zinc Gluconate Nasal Spray Gel - For influenza 7/10 www.hk1180.com
Slide 8: Strong Market Access & Acceptance
Strong Market Access & Acceptance Soaring No. of Hospitals Adopting Wei Jia Extensive Sales & Distribution Network In China 1200 7% 1,000 1000 12 = Beijing 700 800 GR 600 600 CA 500 400 Chengdu Wuhan Shanghai 400 Wuhan Hangzhou 200 150 60 85 Guangzhou 0 2H00 2H01 2H02 2H03 Sales Headquarters Regiona
Slide 9: Impressive Turnaround
Impressive Turnaround HK$ 2001 2002 2003 Sales 22 m 31 m 57 m Profit/(Loss) (57) m (23) m 37 m 9/10 www.hk1180.com
Slide 10: Solid Financial Strength
Solid Financial Strength As At 31 December 2003 Cash & Securities HK$ 87 m Current Assets HK$203 m Total Assets HK$290 m Current Ratio 10.4x Total Liabilities To Assets Ratio 11% 10/10 www.hk1180.com
Slide 11: Thank You
Thank You E \\3 ws, BN waw.hk1180.com
Slide 12: Appendices
Appendices 12 www.hk1180.com
Slide 13: Highly Effective In Combination Therapy Against Hepatitis
Highly Effective In Combination Therapy Against Hepatitis High Effective Rate With Wei Jia: With Without Combination Therapy Wei Jia Wei Jia Severe Chronic HBV 88.9% 40.0% Severe Acute HBV 78.4% 40.0% Source: Wei Jia’s clinical statistics 13/10 www.hk1180.com
Slide 14: Capture Substantial Share In China HBV Drug Market
Capture Substantial Share In China HBV Drug Market § US$1.6 bn market potential § 120 m carriers § 35 m chronic patients § 5 m severe patients Source: The PRC Health Yearbook 1999 14/10 www.hk1180.com
Slide 15: What Is Fibroscutum?
What Is Fibroscutum? § Novel protein § Proven to have suppressing effect on fibrosis and liver cancer § U.S. patent filed for the drug 15/10 www.hk1180.com
Slide 16: Fibroscutum Suppresses Liver Cancer Cell Growth
Fibroscutum Suppresses Liver Cancer Cell Growth Above: HepG2 Cells Before Use Of Fibroscutum Above: HepG2 Cells Reduced After Use Of Fibroscutum Model: Liver Cancer HepG2 Cell Growth Rate % 100 100 80 Cell % 60 40 20 50 0 0 5 10 15 20 25 0 Increasing Fibroscutum Fibroscutum µL Source: City Universit
Slide 17: Fibroscutum Suppresses Fibrosis Of Liver Cells
Fibroscutum Suppresses Fibrosis Of Liver Cells Micronodular 300 Model: Fibroblast Cell NIH-3T3 Normal Liver Cirrhosis 250 200 Relative Cell % 150 100 50 0 Normal Fibroscutum Severe Fibrosis Fibroscutum Only Source: City University Of Hong Kong 17/10 www.hk1180.com
Slide 18: Therapeutic Mechanism Of Fibroscutum
Therapeutic Mechanism Of Fibroscutum Disturb Inhibit the growth EGF function of Tumor Cells Inhibit Bind with fibroblasts’ Prevent Function 1 TGF beta growth Cirrhosis stimulated by TGF beta Fibroscutum Enhance the body’s Th1 immune response Function 2 to Viral Infection and to Certain Cancers 18/10
Slide 19: World's Top Research Team Of Fibroscutum
World’s Top Research Team Of Fibroscutum Prof. Hsiang-Fu. Kung ( ) § Principal inventor of the first anti-hepatitis protein drug Interferon α-a § Member of the Chinese Academy of Sciences § Director and Chair Professor of Institute of Molecular Biology of the University of Hong Kong 19/10 www.hk1180
Slide 20: World's Top Research Team Of Fibroscutum
World’s Top Research Team Of Fibroscutum Prof. Michael Yang ( ) § Professor of Biology and Chemistry Department of the City University of Hong Kong (“City U”) § Postdoctoral Fellow of The Scripps Research Institute, USA § PhD Analytical Chemistry, University of Toronto 20/10 www.hk1180.com
Slide 21: How rhALR Works?
How rhALR Works? § Bind to specific receptor on the liver cell surface § Trigger signal transduction pathways such as mitogen activated kinase pathway (“MAPK”) to regulate cell functions rhALR § Also bind to Jun activation domain-binding protein 1 (JAB1), a co-activator of activating protein 1 (“AP-
Slide 22: Top Research Talent Of rhALR
Top Research Talent Of rhALR Dr. Jun Cheng ( ) § Inventor of rhALR § Deputy Director of Institute of Infectious Diseases, People’s Liberation Army § Doctorate in Medicine, Beijing Medical University § Post doctorate studies at the Department of Immunology and Infectious Diseases, Health Science Cent
Slide 23: Pazufloxacin
Pazufloxacin § New generation antiseptic for China § Quinolone antimicrobials § Efficacious drug for bacterial infections: Ø Bronchitis Ø Complicated urinary tract infections Ø Community-acquired pneumonia Ø Gonorrhea 23/10 www.hk1180.com
Slide 24: Focused & Proactive Sales Strategy
Focused & Proactive Sales Strategy § Focus on the +1,000 infectious disease hospitals § Leverage on vast distribution network § Target audience at professional seminars conference & exhibitions § Expert panel to enhance product image § Dedicated sales and customer support 24/10 www.hk1180.com
Slide 25: Set Up Drug National Distribution Business
Set Up Drug National Distribution Business § National drug distribution license § Distribute local and overseas biopharmaceutical products § Leverage on existing sales infrastructure 25/10 www.hk1180.com
Slide 26: Actively Expand Overseas Markets
Actively Expand Overseas Markets § Wei Jia was sold to Vietnam in 2003 § Wei Jia has been launched in Cambodia, Myanmar and Laos § Consistently exploring sale of Wei Jia to other overseas markets 26/10 www.hk1180.com
Slide 27: Strong R&D Support
Strong R&D Support § Research team in China § Well equipped lab at Shanghai § Collaboration with leading research institutes § Close ties with Chinese Academy of Sciences 27/10 www.hk1180.com
Slide 28: LifeTec's Renowned Scientific Advisors
LifeTec’s Renowned Scientific Advisors § Top liver specialists in China § Top U.S. liver transplant experts § World’s leading medical school professors § SDA Committee Member § Director of Chinese Academy of Sciences 28/10 www.hk1180.com
Slide 29: LifeTec's Renowned Scientific Advisors
LifeTec’s Renowned Scientific Advisors § Prof. Si Chong Wen ( ) § Prof. Wu Shan Ming ( ) § Prof. Wu Xiang Hui ( ) § Prof. Yao Chi Lu ( ) § Prof. Lo Jie Yin ( ) § Dr. Cai Pang ( ) § Prof. Hu Dong Xu ( ) § Prof. Yan Shi Yun ( ) 29/10 www.hk1180.com